Rilzabrutinib Drug Asset Due Diligence Report 2026

This Rilzabrutinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Rilzabrutinib can convert its Small molecule drug profile and BTK biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Rilzabrutinib (query alias: rilzabrutinib)
Modality / target	Small molecule drug; BTK; BTK inhibitors
Highest global status	Approved
Originator	Genzyme Corp.
Active developers	Sanofi, Principia Biopharma, Inc., Sanofi (China) Investment Co. Ltd.

The MCP disease footprint includes Purpura, Thrombocytopenic, Idiopathic, Immunoglobulin G4-Related Disease, Warm autoimmune hemolytic anemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07190196	Phase 3	Recruiting	124	Time to first adjudicated clinical disease flare treated by the investigator during the Blinded Treatment period
NCT07086976	Phase 3	Recruiting	90	Proportion of participants achieving DHR. DHR is defined as an increase of Hb by ≥2 g/dL from baseline on at least two thirds of evaluable scheduled visits between Week 12 and Week 24 (inclusive) in the PAP
NCT07007962	Phase 3	Recruiting	60	Durable platelet response

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Proof-of-concept Study Evaluating Efficacy and Safety of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Who Are Inadequate Responders or Intolerant to Topical Corticosteroids

Phase 2; n=124; evaluation: not stated. Reported fields: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score(Least Squares Mean) = -43.33 Percent change (Standard Error, 6.99); Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score(Least Squares Mean): Least Square Mean Difference = -6.25(95% CI, -31.26 to 18.77), P-Value = 0.6246; Least Square Mean Difference = -3.88(95% CI, -21.97 to 14.21), P-Value = 0.6740; Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score(Least Squares Mean) = -47.21 Percent change (Standard Error, 6.26)

PHASE 3 LUNA3 FINAL EFFICACY AND SAFETY RESULTS FOR RILZABRUTINIB IN THE LONG-TERM EXTENSION PERIOD IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Phase 3; n=69; evaluation: Positive. Reported fields: CR(platelet count ≥100x10^9/L on 2 consecutive visits) = 59.0 %

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Phase 2; n=196; evaluation: Negative. Reported fields: LOAC = 29.0 % ; LOAC = 50.0 % ; LOAC = 38.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Rilzabrutinib addresses Purpura, Thrombocytopenic, Idiopathic, Immunoglobulin G4-Related Disease, Warm autoimmune hemolytic anemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 39 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: BTK records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-08	Roche and Nurix Therapeutics to partner in $2.3bn deal	Phase 3	US$2,300.0M stated total
2026-06-02	Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases	Phase 2	US$112.5M upfront; US$1,030.0M milestones
2026-05-14	Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for treating sickle cell disease by administering a BTK inhibitor”. The milestone feed surfaced a patent-application signal described as “Rilzabrutinib for treating warm antibody autoimmune hemolytic anemia”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO